
The immediate backdrop is the active March–2026 regional war in which the United States and Israel launched coordinated military strikes against Iranian nuclear-related and military infrastructure; those strikes followed months of escalating exchanges in the Gulf and Levant, including attacks by Iranian-aligned proxies and incidents against commercial shipping that had increased from 2024 into early 2026.
The U.S. political environment under President Donald Trump (inaugurated January 20, 2025) and international sanctions regimes tightened around Iran during 2025–2026 have shaped government and institutional behaviour across science, medicine and professional societies.
A coordinated group of researchers has launched a boycott against the American Diabetes Association and its journal, vowing to withhold peer review and manuscript submissions to pressure the organization over conflict-of-interest and publishing-practice concerns (per statnews.com).
Organizers framed the action as necessary to challenge what they describe as undue industry influence within the ADA's structures; statnews reports the campaign comes from researchers themselves rather than patient groups or outside funders.
The boycott's immediate tactic — refusing to perform peer review and to submit new research to the ADA journal — aims to impair the journal's ability to vet and publish work, a lever academically credentialed scientists can use without involving legal or political mechanisms (per statnews.com).
The organizers' public statements, as reported by statnews, focus on transparency in disclosure, editorial independence, and stricter management of conflicts of interest; the article does not quote ADA leadership or provide a response from the association.
Why now: statnews frames the timing as a direct reaction by researchers to perceived persistent problems in ADA governance and journal practices, though the report does not list a single triggering paper, vote, or policy change that immediately preceded the boycott.
The boycott mixes reputational pressure with operational disruption; if sustained, withholding peer review could slow the ADA journal's publication pipeline and raise questions about its standing among researchers who rely on timely peer review and publication to advance careers (per statnews.com).
Absent from the statnews account are specifics about how many researchers have signed on, whether major diabetes research centers back the move, and what metrics organizers will use to declare the boycott successful, leaving key implementation details unreported (per statnews.com).